Highlights

  • FY26 Revenue fell to $11.5 million as US Medicare non-coverage continued to impact volumes.
  • Draft Medicare policy now includes Cxbladder Triage and Triage Plus, marking a major reimbursement milestone.
  • Cash position of $7.8 million supported by $25.4 million Capital raise and reduced monthly burn.
  • Shares rose around 4–5% as investors reacted to improved reimbursement visibility and cost control.

Shares of Pacific Edge Limited (ASX:PEB) moved higher following the release of its audited FY26 financial results, as investors weighed a continued revenue decline against a significant regulatory and reimbursement development in the United States healthcare system.

The company reported a challenging financial year marked by reduced test volumes and lower Operating Revenue, yet the market response reflected optimism around a draft Medicare Local Coverage Determination that could reshape the commercial trajectory of its core diagnostic products.

Share Performance Reflects Re-Rating of Reimbursement Outlook

Pacific Edge’s share price strengthened by nearly 4.8% to 0.22 AUD, extending a recovery trend driven by improving policy visibility in the United States.

Revenue Decline Reflects Prior Coverage Loss and Volume Compression

FY26 results confirmed the financial impact of Medicare non-coverage, with operating revenue falling to $11.5 million from $21.8 million in the prior year. Total revenue declined to $13.6 million, reflecting reduced utilisation of Cxbladder tests in the United States.

Total laboratory throughput decreased by 16.3% to 24,190 tests, driven primarily by a 23.8% reduction in commercial test volumes. The decline was partially offset by growth in selected accounts, including the Southern California Permanente Medical Group, as well as modest expansion in the Asia-Pacific region.

The contraction in US volumes underscores the sensitivity of diagnostic adoption to reimbursement frameworks, particularly in high-cost healthcare markets such as the United States. The absence of Medicare coverage during the reporting period remained the dominant constraint on commercial scale.

Cost Discipline and Reduced Cash Burn Support Financial Stability

While revenue declined, Pacific Edge implemented a significant cost containment program during FY26. Operating expenses were reduced by approximately 9.5% compared to FY25, supported by a smaller US sales force and broader efficiency measures across the organisation.

Net loss after tax increased to $35.8 million from $29.9 million, reflecting revenue pressure, although second-half performance showed some improvement with a reduced loss compared to the first half.

Cash Management also improved during the period. Monthly cash burn decreased from $3.3 million in the first half to $2.4 million in the second half of FY26, reflecting a more disciplined operational structure.

The company ended the year with $7.8 million in cash, cash equivalents, and short-term deposits. This position was subsequently strengthened by a $25.4 million institutional Placement, alongside a retail share purchase plan targeting up to an additional $6 million.

Medicare Draft Coverage Represents Strategic Inflection Point

The most significant development for Pacific Edge came post balance date with the publication of the draft LCD by US Medicare administrator Novitas. The policy proposes coverage for Cxbladder Triage and Triage Plus for intermediate-risk microhematuria patients, marking the first time hematuria evaluation using urine-based biomarkers has been formally positioned for Medicare reimbursement.

The inclusion of Triage Plus is particularly notable given its higher pricing structure of approximately US$1,328 per test compared to US$760 for legacy products. This shift has the potential to materially improve revenue per test and enhance the commercial attractiveness of the company’s diagnostic platform.

The company has also indicated that claim-by-claim reimbursement is now possible under the draft framework, reducing uncertainty for providers considering adoption ahead of final policy implementation.

While the draft LCD is expected to become final by the end of calendar 2026, Market Participants are already treating the development as a partial de-risking of the US reimbursement pathway.

Commercial Strategy Focused on Clinical Adoption and Payer Expansion

Pacific Edge continues to position its commercial strategy around expanding clinical adoption within urology practices and integrated delivery networks. Growth in payer coverage has been achieved across multiple US states through Blue Cross Blue Shield plans and other insurers, collectively covering millions of lives.

The company’s strategy is increasingly centred on embedding Cxbladder into clinical decision pathways for hematuria evaluation, supported by growing real-world evidence and guideline adoption efforts.

In parallel, expansion in Asia-Pacific markets has contributed incremental growth, including clinical pathway implementations at major hospitals in Singapore and Australia.

Clinical Evidence Base Strengthens Long-Term Positioning

During FY26, Pacific Edge expanded its clinical evidence portfolio through multiple studies designed to reinforce the diagnostic value of its products. These include real-world Utility research conducted in Partnership with major healthcare systems, as well as prospective validation studies.

The company also highlighted ongoing development of next-generation tests, including Cxbladder Surveillance Plus, which is aimed at monitoring bladder cancer recurrence. These developments reflect a broader strategy of expanding the diagnostic platform across multiple clinical use cases.

The strengthening of clinical evidence is closely linked to reimbursement success, as payer decisions in the US healthcare system are heavily influenced by guideline inclusion and published validation studies.

Capital Raising Supports Transition Phase

The recent capital raising activity, including the $25.4 million placement and retail offer, reflects the company’s need to fund operations through a transitional phase of reimbursement recovery.

Management has indicated that proceeds will be used to support ongoing commercial operations, product development, and evidence generation efforts. The funding is intended to bridge the period until Medicare coverage becomes effective and commercial payer adoption potentially accelerates.

Market Outlook and Structural Transition

The FY26 results highlight a company operating in a transition phase between reimbursement disruption and potential recovery. Revenue contraction and losses reflect the operational impact of Medicare non-coverage, while the draft LCD introduces a materially different outlook for the medium term.

Investor focus is increasingly centred on whether the draft Medicare policy is converted into final coverage and how quickly commercial test volumes respond once reimbursement is fully restored. The trajectory of payer adoption and physician uptake will remain key determinants of financial performance in FY27 and beyond.

Conclusion

Pacific Edge’s FY26 results present a dual narrative of operational pressure and strategic progress. While revenue declines and losses reflect the disruption caused by US Medicare non-coverage, the emergence of a draft reimbursement policy represents a potentially significant turning point for the company’s core diagnostic platform. The coming year is likely to be defined by the transition from policy approval to commercial execution, with investor sentiment closely tied to the pace of reimbursement normalisation and volume recovery across its US Business.